doi: 10.3389/fmed.2024.1449037 Received 24 June 2024 Accepted 23 September 2024 Published 07 October 2024 Volume 11 - 2024 Edited by Yue Liu, Boston Childrens Hospital, Harvard Medical School, United States Reviewed by Kaige Chen, Wake Forest University, United States Yi-Kai Hong, Northwestern University, United States Updates Copyright 2024 Xie, Cao, Shu, Liu and Zhang
The global burden of disease attributable to high body mass index in 195 countries and territories, 1990-2017: An analysis of the Global Burden of Disease Study
Inhibition or down-regulation of ODC1 breaks this vicious cycle and promotes astrocytic detoxification of -amyloid
However, these findings are preliminaryno FDA-approved clinical trial has tested GLP-1 medications specifically for smoking cessation yet